Oxcarbazepine add-on for drug-resistant partial epilepsy

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 11, 2016, Pages

  Atim Oluk, Margaret ^a   Jackson, Cerian F ^b   Marson, Anthony G ^b  

^a Wales Deanery   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OXCARBAZEPINE;

ADD ON THERAPY; ARTICLE; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG RESISTANT EPILEPSY; DRUG TOLERABILITY; FOCAL EPILEPSY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STUDY DESIGN; SYSTEMATIC REVIEW;

EID: 84997113484     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD012433     Document Type: Article

References (25)

1. Bell GS, Neligan A, Sander JW. An unknown quantity - the worldwide prevalence of epilepsy. Epilepsia 2014;55(7):958-62.
2. Burton K, Rothgathe J, Whittaker RG, Mankad K, Hunter E, Burton MJ, et al. Co-morbidity of epilepsy in Tanzanian children: a community-based case-control study. Seizure 2012;21(3):169-74.
3. Cochrane HC, Baker GA, Chadwick DW. Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards. Epilepsia 1998;39(10):1088-97.
4. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346(8968):140-4.
5. Commission on classification and terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30(4):389-99.
6. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55(4):475-82.
7. Flesch G. Overview of the clinical pharmacokinetics of oxcarbazepine. Clinical Drug Investigation 2004;24(4):185-203.
8. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, et al. ILAE Subcommission on AED Guidelines: updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54(3):551-63.
9. Brozek J, Oxman A, Schunemann H. GRADEPro Version 3.6 for Windows. GRADE Working Group, 2004.
10. Grant SM, Faulds D. Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992;43(6):873-8.
11. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
12. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy. Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2009;51(6):1528-1167.
13. Kang HC1, Hu Q, Liu XY, Liu ZG, Zeng Z, Liu JL, et al. A follow up study on newer anti-epileptic drugs as add-on and monotherapy for partial epilepsy in China. Chinese Medical Journal 2012;125(4):646-51.
14. Kirkham JJ, Swan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:365.
15. Kwan P, Brodie MJ. Early identification of refractory epilepsy. New England Journal of Medicine 2000;342(5):314-9.
16. LaFrance WC Jr, Kanner AM, Hermann B. Chapter 20: psychiatric comorbidities in epilepsy. International Review of Neurobiology 2008;83:347-83.
17. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org/.
18. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997;38(8):859-80.
19. Panebianco M, Rigby A, Weston J, Marson AG. Vagus nerve stimulation for partial seizures. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD002896.pub2]
20. Privitera MD. Evidence-based medicine and antiepileptic drugs. Epilepsia 1999;40(Suppl 5):S47-S56.
21. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) Version 5.3. Copenhagen. The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
22. Sander JW, Hart YM, Johnson AL, Shorvon SD. National General Practice Study of Epilepsy: newly diagnosed epileptic seizures in a general population. Lancet 1990;336(8726):1267-71.
23. Schunemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.
24. Shorvon S. Handbook of Epilepsy Treatment. 2nd Edition. Oxford: Blackwell Science, 2013.
25. West S, Nolan, S, Cotton J, Candhi S, Weston J, Sudan A, et al. Surgery for epilepsy. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD010541.pub2]